From: One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study
Oxygen only (N = 61) | CPAP (N = 136) | IMV (N = 90) | p | |
---|---|---|---|---|
Age (years), median [Q1–Q3] | 60.7 [53.7, 71.4] | 60.7 [53.0, 67.5] | 60.3 [54.4, 67.0] | 0.46 |
Male gender, N (%) | 33 (54) | 106 (78) | 74 (82) | < 0.001 |
BMI (kg/m2), median [Q1–Q3] | 27.4 [24.5, 31.5] | 28.7 [26.6, 31.3] | 28.3 [26.3, 31.4] | 0.15 |
Smoking Historya, N (%) | 0.09 | |||
No | 40 (85) | 76 (64) | 47 (64) | |
Active-prior | 7 (11) | 43 (32) | 26 (29) | |
Comorbidities | ||||
Cardiovascular diseases, N (%) | 10 (16) | 31 (23) | 24 (27) | 0.32 |
Hypertension, N (%) | 19 (31) | 39 (29) | 24 (27) | 0.82 |
Cerebrovascular diseases, N (%) | 1 (2) | 3 (2) | 1 (1) | 1.00 |
Asthma, N (%) | 8 (13) | 4 (3) | 4 (4) | 0.02 |
OSAS, N (%) | 2 (3) | 3 (2) | 1 (1) | 0.76 |
Chronic kidney diseases, N (%) | 4 (7) | 2 (1) | 3 (3) | 0.12 |
Liver diseases, N (%) | 1 (2) | 3 (2) | 0 (0) | 0.43 |
Diabetes, N (%) | 10 (16) | 18 (13) | 13 (14) | 0.84 |
Prior cancer, N (%) | 5 (8) | 2 (1) | 5 (6) | 0.05 |
No. of comorbidities, N (%) | - | |||
0 | 20 (33) | 64 (47) | 36 (40) | |
1 | 26 (43) | 42 (31) | 34 (38) | |
2 | 9 (15) | 23 (17) | 16 (18) | |
≥ 3 | 6 (10) | 7 (5) | 4 (4) | |
Treatments associated with COVID-19 | ||||
Systemic steroidb, N (%) | 15 (30) | 62 (56) | 44 (59) | 0.002 |
Prophylactic heparinb, N (%) | 15 (30) | 53 (48) | 41 (55) | 0.02 |
Tocilizumabb, N (%) | 3 (6) | 17 (15) | 17 (23) | 0.04 |
Remdesivirc, N (%) | 1 (2) | 2 (2) | 11 (15) | 0.001 |
Mucolyticsc, N (%) | 10 (20) | 32 (29) | 35 (47) | 0.004 |
Hyperimmune Plasmac, N (%) | 0 (0) | 1 (1) | 1 (1) | 1.000 |
Lopinavir/ritonavirc, N (%) | 19 (38) | 73 (66) | 36 (49) | 0.002 |
Hydroxychlorokined, N (%) | 39 (78) | 95 (87) | 58 (79) | 0.23 |